Health Innovation Euregion 2025

12 Jun 2025 | Netherlands

Register
Register
Register

ExpertiseUpdated on 4 April 2025

Oligodendrocyte biology and remyelination platform

An Voets

business developer BIOMED at Hasselt University - Biomedical Research Institute

Diepenbeek, Belgium

About

Are you developing new therapies for neurodegenerative disease that target oligodendrocyte biology or de- and remyelination?

▶ Progress your development programs faster by building on our expertise glial cell biology, neuroscience, and lipid metabolism.

▶ Our validated models are continuously exploited in proprietary research programs and service activities for the private sector.

▶ We are keen on creating collaborative and longlasting partnerships by meeting rapidly changing needs and requirements in a flexible way and delivering on our promises.

POSSIBLE APPLICATIONS

• Test the therapeutic activity of candidate therapies on oligodendrocyte biology and remyelination in vitro at three levels: differentiation and proliferation of oligodendrocyte precursor cells (OPCs), migration behaviour of OPCs and axon-wrapping potential. Multiple conditions can be tested in parallel.

• Test the effect of therapies in a more complex multicellular brain environment using ex vivo in brain slice cultures. Multiple conditions can be tested in parallel.

• Test your candidate therapies in in vivo models which includes a battery of functional, structural, and clinical outcome measures.

Similar opportunities